Audited Financial Results for the year ended March 31, 2025<BR> Recommendation of Dividend @ 10% on paid up capital of the company

EBITDA margin expansionNet loss reportedNegative operating cash flowResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-12.4%Reaction day

₹399.90

prior close

₹350.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.1%-12.5% vs market

Pharmaceuticals peers, median of 147sector-0.1%-12.4% vs sector

On the reaction day the stock moved 12.5 pts less than Nifty Microcap 250 and 12.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.6

10m

-1.6

15m

-1.4

30m

+0.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-12.4+0.1-12.5-0.1-12.4

Next day

-12.5-0.2-12.3-0.2-12.3

-12.5+0.3-12.8-0.2-12.2

-12.0+0.9-12.8+0.0-12.0

-12.4+0.8-13.2+0.0-12.4

-13.2+2.2-15.4+0.6-13.9

-13.2+3.4-16.6+1.4-14.7

15d

-14.0-0.8-13.2-2.9-11.1

-12.7+2.9-15.7+0.3-13.0

-13.2+0.8-14.1-0.4-12.9

-20.7+0.0-20.7-3.2-17.5

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 147Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Samrat Pharmachem Limited reported audited standalone results for FY25 with revenue from operations of Rs. 28,586.05 lakhs, a modest 1.5% rise over FY24's Rs. 28,158.12 lakhs. Profit after tax jumped sharply to Rs. 711.22 lakhs from Rs. 216.26 lakhs in FY24, nearly tripling year-on-year, driven by lower material costs and improved operating margins. However, the standalone quarter (Q4 FY25) showed a loss of Rs. 39.92 lakhs versus a Rs. 139.53 lakh profit in Q4 FY24, and revenue in Q4 fell about 14% to Rs. 7,120.31 lakhs. The Board has recommended a 10% dividend (Rs. 1.00 per share on Rs. 10 face value), subject to shareholder approval at the 33rd AGM on September 25, 2025. Statutory auditors Shah & Savla LLP issued an unmodified (clean) opinion on the results.

Likely market impact

Strong full-year profit growth and a 10% dividend are positive for shareholders, but the Q4 loss, sharp decline in operating cash flow (net cash used of Rs. 1,009 lakhs vs Rs. 941 lakhs generated last year), and near-depletion of cash balance (from Rs. 966.75 lakhs to Rs. 4.83 lakhs) raise concerns about working capital strain and short-term liquidity. Investors should weigh the strong annual earnings print against the weakening quarter-end momentum and cash position.